086060 — Genebiotech Co Income Statement
0.000.00%
- KR₩34bn
- KR₩27bn
- KR₩79bn
- 71
- 88
- 15
- 63
Annual income statement for Genebiotech Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 58,245 | 59,119 | 62,814 | 82,759 | 79,477 |
Cost of Revenue | |||||
Gross Profit | 9,699 | 9,572 | 7,577 | 10,498 | 13,793 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 57,277 | 57,354 | 63,178 | 81,118 | 76,114 |
Operating Profit | 968 | 1,765 | -365 | 1,640 | 3,363 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 350 | -420 | -838 | 1,815 | 3,374 |
Provision for Income Taxes | |||||
Net Income After Taxes | -27.2 | -61.5 | -484 | 1,523 | 2,591 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 847 | -2,341 | -484 | 1,523 | 2,591 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 847 | -2,341 | -484 | 1,523 | 2,591 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 88.7 | -16.2 | -44 | 180 | 352 |
Dividends per Share |